VistaGen Therapeutics (VTGN)
Develops intranasal pherine candidates for psychiatric, women's-health, and cancer-supportive-care conditions.
Something off on this page? Send us feedback.
Develops intranasal pherine candidates for psychiatric, women's-health, and cancer-supportive-care indications, while present revenue comes from sublicense and other arrangements. It sponsors development, relying on external trial and manufacturing providers and regional partners; it has no approved or marketed products.
Develops intranasal pherine candidates designed to modulate neural circuits without systemic drug exposure. Its named programs include fasedienol for social anxiety disorder, itruvone for major depressive disorder, refisolone for menopausal vasomotor symptoms, PH15 for mental-fatigue-related psychomotor impairment, and PH284 for cancer cachexia. AV-101 is held principally for partnering.
Operates from South San Francisco, with clinical and regulatory activity predominantly directed at the United States. It sponsors development while CROs run trials and CDMOs handle all manufacturing; fasedienol is licensed to AffaMed across parts of Asia while rights elsewhere are retained. There are no approved or marketed products, and revenue comes from sublicense and other arrangements. Further progress depends on controlled clinical evidence, regulatory agreement, financing, third-party execution, and partners.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 17, 2025 | Jefferies | Downgrade | Target: $0.20 | Target: $0.90 |
| Dec 17, 2025 | Stifel Nicolaus | Target | Target: $12 | Target: $1 |
| Dec 17, 2025 | Maxim Group | Downgrade | ||
| Dec 17, 2025 | William Blair | Downgrade | ||
| Nov 17, 2025 | Stifel Nicolaus | Target | Target: — | Target: $12 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $31.7M · Total debt $783.0K · Total assets $35.7M · Shareholders' equity $24.5M
- Revenue
- $1.5M
- Operating income
- −$13.3M
- Net income
- −$13.0M
No dividends on record.
| Institutions | 26.54% | 11.78M shares | |
|---|---|---|---|
| 58 holders · as of Jun 30, 2026 | |||
| Insiders | 0.35% | 155.5K shares | |
| 5 holders · as of Jul 2, 2026 | |||
| Other | 73.11% | 32.44M shares | |
| remainder | |||
44.38M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Commodore Capital LPInstitution | 6.28% | 2.79M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.55% | 1.57M | as of Jun 30, 2026 |
Two Sigma Investments, LPInstitution | 1.91% | 847,992 | as of Jun 30, 2026 |
Acadian Asset Management LLCInstitution | 1.79% | 794,579 | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 1.65% | 730,500 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Vanda Pharmaceuticals
Late-stage, on-demand social-anxiety program challenging fasedienol.
- Axsome Therapeutics
Marketed Auvelity sets an established MDD treatment benchmark.
- Johnson & Johnson
Marketed Caplyta competes for adjunctive MDD treatment.
- Tonix Pharmaceuticals
Early intranasal oxytocin research overlaps in social anxiety.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics | $0.4048 | +61.02% | $11.2M | — | — | 4.5 | +504.9% |
| Vanda Pharmaceuticals | $5.00 | −4.04% | $313.3M | — | — | 1.5 | −3.9% |
| Axsome Therapeutics | $197.45 | −2.78% | $10.45B | — | 1,178.0 | 13.5 | +44.2% |
| Johnson & Johnson | $269.93 | +0.27% | $648.72B | 31.2 | 22.7 | 6.6 | +6.6% |
| Tonix Pharmaceuticals | $10.16 | −4.06% | $168.8M | — | — | 5.8 | +577.9% |
| Median | 31.2 | 600.4 | 6.2 | +25.4% |